Articles tagged with Coinfection
Researchers surveyed 7 pathogens in wild native snakes, finding Ophidiomyces and Raillietiella orientalis as most important infectious agents. Rattlesnakes are most likely to host these pathogens, with increased risks of ophidiomycosis and parasitic lung infection.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
A Dartmouth study found that plasmids can form tight clusters within bacterial communities, making them resistant to antibiotics and clinical treatments. This phenomenon introduces a new avenue for bacterial infections to become more difficult to treat.
The study will select the exact phage that is appropriate for each patient's bacteria, and aims to reduce antibiotic use and healthcare costs. Bacteriophages have been shown to be effective against resistant bacteria causing urinary tract infections.
Public Health Alerts provide concise, data-driven information on disease outbreaks and urgent health events. The new series, launched by NEJM Evidence and CIDRAP, offers expert-reviewed reports to support public health evidence-based care.
Research suggests that co-infections such as Epstein-Barr virus and tuberculosis may contribute to long COVID symptoms. These infections could leave the immune system compromised, triggering persistent symptoms. The study's findings offer new lines of investigation into effective treatments for long COVID.
A study found that hepatitis C treatment with direct-acting antivirals (DAAs) improves immune function in individuals co-infected with HIV and HCV, even in those with advanced liver disease. The treatment resulted in significant declines in inflammation and liver damage markers.
A University of Houston professor has received funding to develop effective treatments for Cryptosporidium infections, which cause severe diarrhea and have no existing cure. The team aims to design drugs that target the parasite's enzyme CDPK1 to minimize systemic exposure and maximize efficacy.
A study published in PLOS Neglected Tropical Diseases has shown that combining country-level information with individual-level variables can improve the identification of soil-transmitted helminth infections among migrant populations. Researchers found that country-level indicators are stronger predictors than individual-level variable...
A new retrospective study found that nearly half of patients with fever of unknown origin in sub-Saharan Africa had a detectable pathogen, including bacterial strains and hemorrhagic fever viruses. The study highlights the need for strengthened laboratory capacity to improve diagnosis and treatment.
A pilot study found evidence of human co-infections with Bartonella and Babesia odocoilei in six out of seven patients with chronic, non-specific illness. The discovery could lead to better diagnoses and treatments for patients with these infections.
Researchers developed a PCR test that accurately identifies the causative agent of visceral leishmaniasis, a neglected disease affecting Brazil and Latin America. The test can detect co-infection by both Leishmania infantum and Crithidia, with infection by Crithidia more frequent than previously thought.
A child patient was co-infected with Leishmania infantum and an unnamed Crithidia parasite species, revealing a rare case of non-ulcerated cutaneous leishmaniasis. Genome sequencing confirmed the presence of both parasites, sparking new research questions on disease transmission and host susceptibility.
A preclinical study demonstrates the effectiveness of VIR-3434 in preventing viral dissemination and reducing viral particles in a mouse model for HBV/HDV coinfection. The monoclonal antibody neutralises all known genotypes of HBV and HDV, providing a potential new option for treating chronic hepatitis B and D.
Researchers link acute severe hepatitis in children to co-infections with multiple common viruses, including AAV2. The study suggests that getting more than one infection may have made children vulnerable to severe hepatitis.
Researchers at Western University discovered that Staphylococcus aureus bacteria enhances SARS-CoV-2 replication by 10- to 15-fold. This finding could inform the development of new therapeutic approaches for COVID-19 patients with bacterial co-infections.
Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.
A recent study found that bacterial co-infection in COVID-19 patients significantly increased the risk of death, intensive care unit admission, and mechanical ventilation. The study reviewed 13,781 COVID-19 inpatient encounters and identified laboratory trends associated with COVID-19 bacterial co-infection.
Research on COVID-19 variants reveals that infants and toddlers with co-infections are significantly more likely to need oxygen therapy and ICU-level care. Co-infection rates were highest during the delta variant, followed by omicron and alpha.
A systematic review of 36 studies found that influenza vaccination reduced the risk of SARS-CoV-2 infection by 20% and poor outcomes like ICU admission and death by 17-31%. The findings suggest that routine influenza vaccination could offer non-specific immunity against COVID-19 symptoms.
Co-infection with gut parasites increases shedding of respiratory bugs like Bordetella bacterium, leading to higher probability of onward transmission. This study in rabbits has broad implications for human populations and suggests targeting treatment of helminths could be an effective way to reduce disease outbreaks.
Researchers at the University of Missouri School of Medicine discovered a high prevalence of COVID-19 co-infections with the flu during the 2021-2022 flu season, peaking at 48% in October 2021. Vaccinations against both viruses appeared to offer protection against co-infections.
A recent study finds that fungal infections during the pandemic are a significant public health problem with limited treatment options. The interaction between pathogen and host may be different in people with compromised immunity, leading to increased mortality rates among severe COVID-19 patients.
New research found that coinfection with influenza A virus can significantly suppress SARS-CoV-2 replication in the lung. This effect can persist even after clearance of influenza A virus, suggesting potential factors that restrict SARS-CoV-2 growth.
A study from the University of Birmingham and National Institutes of Health found that antibiotics can lead to fungal infections by disrupting the gut's immune system. Using immune-boosting drugs alongside antibiotics may reduce health risks associated with these complex infections.
Researchers found that one viral protein suppresses infection with hepatitis E. However, experimental studies in mice revealed a different pattern, suggesting the two viruses affect each other in complex ways. Further analysis of liver cells is needed to shed light on the underlying causes of co-infection.
A study found that higher doses of antibiotics are needed to eliminate bacterial infections with other microbes present. Researchers developed a model of the human airways to replicate poly-microbial infections, which often persist despite treatment in people with cystic fibrosis and other lung diseases.
Researchers found that starting combined antiretroviral therapy against simian immunodeficiency virus two weeks after infection significantly reduced chronic immune activation, SIV replication, and latent TB reactivation. This study contributes to the growing evidence on the complex interaction between HIV and tuberculosis.
Researchers found 2.4 times the rate of arbovirosis as originally reported, including coinfections, suggesting underestimation of the incidence of the three viruses. The study enriches epidemiological information on these arboviruses, which can help improve estimates of burden and resource allocation.
Scientists at the University of Nottingham found a plant-based antiviral treatment to be effective in blocking the highly infectious SARS-CoV-2 Delta variant. The novel natural antiviral drug, thapsigargin, was shown to trigger a broad-spectrum host-centred antiviral innate immune response against all variants of the virus.
Researchers developed a viral panel that enables simultaneous testing for SARS-CoV-2 and common respiratory viruses, providing insight into coinfections and viral spread. The tool helps predict and mitigate future outbreaks by tracking novel viral variants and their patterns of spread.
A Belgian case report documents a 90-year-old woman's simultaneous infection with two different SARS-CoV-2 variants of concern: B.1.1.7 (UK) and B.1.351 (South Africa). The patient developed rapidly worsening respiratory symptoms, leading to death. This is one of the first documented cases of co-infection with VOCs.
A study found that co-infection with blood flukes and Helicobacter pylori reduces stomach inflammation by misdirecting immune cells to the liver. The interaction may limit vaccine effectiveness but also provides protection against cirrhosis, a common complication of schistosomiasis.
A study led by Georgia State University found that Ugandan youth with both HIV and sexually transmitted infections are more likely to engage in problem drinking. Co-infection rates among youth living in slums of Kampala, Uganda are significantly higher than other areas of sub-Saharan Africa.
Researchers aim to understand how malarial infections impact people exposed to Ebola virus, with a goal of developing tailored therapeutics for co-infection cases. The study will assess molecular impacts using an animal model and may involve testing in nonhuman primates.
Research reveals that co-infection with two common gut pathogens, Giardia lamblia and enteroaggregative Escherichia coli, increases weight loss and impairs metabolism in mice. The study provides new insights into the impact of gut microbe interactions on malnutrition in children.
A recent study led by Colorado State University researchers found that Aedes aegypti mosquitoes can transmit multiple viruses simultaneously, including Zika, chikungunya, and dengue. The findings contradict existing research on coinfections and suggest that these simultaneous transmissions may be more common than previously thought.
Studies presented at The International Liver Congress 2016 show differing perspectives on direct-acting antiviral (DAA) treatment efficacy in patients co-infected with HIV and HCV. While one study found lower SVR12 rates in co-infected patients, another study showed no statistically significant impact of HIV co-infection on DAAs.
Researchers found that all ticks contained symbiotic bacterial species, while over half were infected with multiple pathogens. The study highlights the importance of accounting for interactions between symbionts and pathogens in tick-borne disease diagnosis and treatment.
A global study reveals 2.3 million people co-infected with HIV and hepatitis C, with a significant burden in Eastern Europe and central Asia. The study highlights the need for improved integrated HIV/HCV services and increased screening and treatment to reduce morbidity and new infections.
A study has created global maps showing the geographical limits of chikungunya and dengue viruses, highlighting a rapid expansion in chikungunya's global extent. The research emphasizes the need for improved diagnostic tests and clear protocols for controlling both diseases.
Co-infection with Epstein-Barr virus (EBV) may make a survivable malaria parasite infection lethal, according to experimental results with mice. EBV infection can suppress the immune system, allowing malaria parasites to take hold.
The daclatasvir-sofosbuvir combination was highly effective and well-tolerated in treating hepatitis C virus (HCV) patients with HIV co-infection. Across genotypes 1-4, the treatment resulted in a sustained virologic response rate of 97% at 12 weeks post-treatment.
Research reveals that competing for the same host plant, different pathogen strains change disease dynamics, leading to more severe epidemics. The study highlights the importance of accounting for coinfection when designing disease prevention efforts.
Dr. Jon McCullers reviews the co-pathogenesis of influenza viruses with bacteria, highlighting complex interactions leading to severe disease and increased morbidity. He calls for large-scale studies to unlock unanswered questions about co-infections and viruses to prevent future pandemics.
Researchers at Rhode Island Hospital found that patients co-infected with H1N1 pandemic virus and a second respiratory virus experienced similar outcomes as those with single-virus infections. Despite increased risk of secondary bacterial pneumonia, co-infection was not linked to hospital admission or ICU treatment.
A new study by Michigan State University found that about four percent of HIV-positive individuals also have hepatitis, highlighting the need for stronger protections against co-infection. The study reveals that behaviors putting people at risk of HIV also increase their risk of getting hepatitis B or C.
A new video article in JoVE presents a novel technique to study interactions between HIV-1 and Plasmodium falciparum in cultured human cells. This method allows scientists to explore different parameters of co-infection, enabling better understanding of the cellular level interactions between these two deadly diseases.
Researchers have confirmed a rare incidence of individuals becoming infected with both seasonal and pandemic strains of the flu at the same time. Experts say this highlights the ongoing risk of distinct flu viruses combining in human hosts, particularly in Southeast Asia where avian influenza and pandemic H1N1 are prevalent.
A clinical trial in Cambodia found that starting anti-HIV therapy two weeks after beginning TB treatment boosts survival rates for HIV-infected adults with weak immune systems. This approach, compared to waiting eight weeks, shows a significant difference in mortality rates among participants.